ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Targeting mTOR with vistusertib attenuates metabolic steatohepatitis and prevents HCC development.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMetabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disorder characterised by lipid accumulation, leading to inflammation, hepatocellular injury, varying degrees of fibrosis, and ultimately hepatocellular carcinoma (HCC). Despite recent advances in drug discovery (approval of resmetirom and semaglutide), MASH remains an unmet medical need, highlighting the need for new therapies to halt disease progression and prevent complications such as HCC. This study aimed to investigate the therapeutic effect of the mTORC1/2 inhibitor (vistusertib) against the spectrum of liver disorders.
methodsPalmitic/oleic acid-treated HepG2, HSC-LX2 cells, LPS-stimulated RAW264.7, HHSECs, and TGF-β-activated HSC-LX2 cells were used to evaluate the therapeutic potential of vistusertib across liver disease models (n = 3). In vivo efficacy against inflammation, fibrosis, and HCC was assessed using streptozotocin (insulin resistance) and high-fat diet-induced (STAM) MASH models (n = 6), with molecular analyses of oxidative stress, fibrotic, and oncogenic markers confirming broad hepatoprotective activity.
resultsVistusertib significantly (p < 0.001) reduced lipid accumulation, LPS-driven inflammation, and TGFβ-induced fibrosis in various in vitro models. It also suppressed cell migration (HepG2), sphere formation, and expression of cancer stem cell markers at low concentrations. In the STAM mouse model (C57BL/6 with streptozotocin and high-fat diet), vistusertib significantly (p < 0.05) decreased hepatic lipid accumulation, de novo lipogenesis, and hepatocellular ballooning. MASH-induced fibrotic markers and collagen deposition were markedly attenuated via mTOR signalling modulation. Importantly, vistusertib reduced tumour nodule formation, suggesting its ability to block MASH progression to HCC, with a confirmed favourable safety profile.
conclusionOur findings identify vistusertib as a promising candidate for MASH, capable of mitigating disease progression and preventing MASH-to-HCC transition, highlighting its potential in managing metabolic liver disorders.
Indexed as
Identifiers
42189199What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.